remikiren

Action and Spectrum

Actions and spectrum: 

Remikiren is specific for renin and does not lower arterial pressure through unrelated mechanisms, as demonstrated by a few in vivo experiments. 

Drug Interaction

Adverse Reaction

Frequency not defined 

Syncope 

Acute kidney injury 

Hypotensive episodes 

Renal vasodilatation 

Negative sodium balance 

Diarrhea  

Hypokalemia  

Cough  

Black Box Warning

No specific black box warnings are available for this drug 

Contraindication / Caution

Contraindication/Caution: 

Contraindication: 

Hypersensitivity 

Angioedema  

Pregnancy / Lactation

Pregnancy consideration:  

USFDA pregnancy category: C 

Lactation:  

Data about the excretion of Remikiren into human milk is not known 

Pregnancy category:  

Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester. 

Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.   

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.    

Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   

Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.    

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology: 

Remikiren is an angiotensin inhibitor 

Pharmacodynamics: 

Renin-inhibitors like Remikiren, which can be taken orally, have been shown to lower blood pressure in people with essential hypertension. There is no data available on the effects of Remikiren on the kidneys in humans. A single oral dosage of Remikiren can cause renal vasodilation in patients with essential hypertension, even though there is a marked drop in blood pressure and no effect on GFR. A more activated renin-angiotensin system results in a more pronounced systemic and renal hemodynamic response. 

Pharmacokinetics: 

Absorption 

It is absorbed rapidly upon oral administration 

Distribution 

83% of the drug is known to be protein-bound 

Metabolism 

Data about the metabolism and excretion of Remikiren is unknown. 

Adminstartion

Administration: 

The drug has to be administered orally before or after food 

Patient Information Leaflet

Patient information leaflet 

Generic Name: remikiren 

Why do we use Remikiren? 

ACE inhibitors and angiotensin II receptor antagonists are two medications that effectively treat cardiovascular diseases by targeting the renin-angiotensin system. However, the lack of effective orally active renin inhibitors with reasonable synthesis costs and bioavailability has prevented clinical use of the system’s most obvious target, the rate-limiting enzyme renin. Remikiren is a drug belonging to the class of renin inhibitors, which is indicated in the treatment of hypertension.